These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24338330)

  • 1. Prime-boost vaccination with plasmid DNA followed by recombinant vaccinia virus expressing BgGARP induced a partial protective immunity to inhibit Babesia gibsoni proliferation in dogs.
    Cao S; Mousa AA; Aboge GO; Kamyingkird K; Zhou M; Moumouni PF; Terkawi MA; Masatani T; Nishikawa Y; Suzuki H; Fukumoto S; Xuan X
    Acta Parasitol; 2013 Dec; 58(4):619-23. PubMed ID: 24338330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs.
    Fukumoto S; Tamaki Y; Okamura M; Bannai H; Yokoyama N; Suzuki T; Igarashi I; Suzuki H; Xuan X
    Vaccine; 2007 Jan; 25(7):1334-41. PubMed ID: 17055131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and growth inhibitory efficacy of the prime-boost immunization regime with DNA followed by recombinant vaccinia virus carrying the P29 gene of Babesia gibsoni in dogs.
    Fukumoto S; Tamaki Y; Igarashi I; Suzuki H; Xuan X
    Exp Parasitol; 2009 Dec; 123(4):296-301. PubMed ID: 19712674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster.
    Wang G; Yu L; Efstratiou A; Moumouni PFA; Liu M; Guo H; Gao Y; Cao S; Zhou M; Li J; Ringo AE; Xuan X
    Acta Parasitol; 2018 Jun; 63(2):368-374. PubMed ID: 29654677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of Babesia gibsoni culture-derived exoantigens against the challenge infection in dogs.
    Sunaga F; Arai S; Itoh S; Taharaguchi S
    Parasitol Res; 2014 May; 113(5):1681-6. PubMed ID: 24535736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK.
    Ramiro MJ; Zárate JJ; Hanke T; Rodriguez D; Rodriguez JR; Esteban M; Lucientes J; Castillo JA; Larraga V
    Vaccine; 2003 Jun; 21(19-20):2474-84. PubMed ID: 12744881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice.
    Zhang G; Huong VT; Battur B; Zhou J; Zhang H; Liao M; Kawase O; Lee EG; Dautu G; Igarashi M; Nishikawa Y; Xuan X
    Parasitology; 2007 Sep; 134(Pt 10):1339-46. PubMed ID: 17506929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
    Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
    Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunisation of cattle against Babesia bovis combining a multi-epitope modified vaccinia Ankara virus and a recombinant protein induce strong Th1 cell responses but fails to trigger neutralising antibodies required for protection.
    Jaramillo Ortiz JM; Paoletta MS; Gravisaco MJ; López Arias LS; Montenegro VN; de la Fournière SAM; Valenzano MN; Guillemi EC; Valentini B; Echaide I; Farber MD; Wilkowsky SE
    Ticks Tick Borne Dis; 2019 Oct; 10(6):101270. PubMed ID: 31445874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of dogs against heterologous Babesia canis infection using antigens from culture supernatants.
    Schetters TP; Kleuskens JA; Scholtes NC; Gorenflot A; Moubri K; Vermeulen AN
    Vet Parasitol; 2001 Sep; 100(1-2):75-86. PubMed ID: 11522408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a recombinant Babesia canis supernatant antigen that protects dogs against virulent challenge infection.
    Moubri K; Kleuskens J; Van de Crommert J; Scholtes N; Van Kasteren T; Delbecq S; Carcy B; Précigout E; Gorenflot A; Schetters T
    Vet Parasitol; 2018 Jan; 249():21-29. PubMed ID: 29279083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine strategies against Babesia bovis based on prime-boost immunizations in mice with modified vaccinia Ankara vector and recombinant proteins.
    Jaramillo Ortiz JM; Del Médico Zajac MP; Zanetti FA; Molinari MP; Gravisaco MJ; Calamante G; Wilkowsky SE
    Vaccine; 2014 Aug; 32(36):4625-32. PubMed ID: 24968152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization and antigenic properties of a novel Babesia gibsoni glutamic acid-rich protein (BgGARP).
    Mousa AA; Cao S; Aboge GO; Terkawi MA; El Kirdasy A; Salama A; Attia M; Aboulaila M; Zhou M; Kamyingkird K; Moumouni PF; Masatani T; El Aziz SA; Moussa WM; Chahan B; Fukumoto S; Nishikawa Y; El Ballal SS; Xuan X
    Exp Parasitol; 2013 Oct; 135(2):414-20. PubMed ID: 23968686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset and duration of immunity against Babesia canis infection in dogs vaccinated with antigens from culture supernatants.
    Schetters TP; Kleuskens JA; Scholtes NC; van de Crommert J; Krijnen E; Moubri K; Gorenflot A; Vermeulen AN
    Vet Parasitol; 2006 May; 138(1-2):140-6. PubMed ID: 16504401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Babesia gibsoni ribosomal phosphoprotein P0 induces cross-protective immunity against B. microti infection in mice.
    Terkawi MA; Jia H; Zhou J; Lee EG; Igarashi I; Fujisaki K; Nishikawa Y; Xuan X
    Vaccine; 2007 Mar; 25(11):2027-35. PubMed ID: 17229504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of different heterologous prime-boost immunization strategies against Babesia bovis using viral vectored and protein-adjuvant vaccines based on a chimeric multi-antigen.
    Jaramillo Ortiz JM; Molinari MP; Gravisaco MJ; Paoletta MS; Montenegro VN; Wilkowsky SE
    Vaccine; 2016 Jul; 34(33):3913-9. PubMed ID: 27269058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with recombinant surface antigen P50 of Babesia gibsoni expressed in insect cells induced parasite growth inhibition in dogs.
    Fukumoto S; Tamaki Y; Shirafuji H; Harakawa S; Suzuki H; Xuan X
    Clin Diagn Lab Immunol; 2005 Apr; 12(4):557-9. PubMed ID: 15817768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.
    Gonzalo RM; del Real G; Rodriguez JR; Rodriguez D; Heljasvaara R; Lucas P; Larraga V; Esteban M
    Vaccine; 2002 Jan; 20(7-8):1226-31. PubMed ID: 11803085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.